Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer

Aerie Pharmaceuticals announced that Peter F. Lang will join the company as Chief Financial Officer, effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals, and become a member of the Aerie Executive Committee.

“I am pleased to welcome Peter to our leadership team,” said Raj Kannan, Chief Executive Officer. “His extensive experience in investment banking and in helping life science companies raise, manage and deploy capital, including business development and M&A transactions, will be important to maximizing shareholder value. I am confident Peter will provide strong leadership and will be an excellent addition to the Aerie team.”

“I have dedicated my career to working with life science companies to help them optimize their growth objectives, financing strategy, capital structure and return on capital, so that they can successfully advance their business plan and meet the needs of patients. I am very pleased to join Aerie at this exciting time, with a growing glaucoma commercial franchise, a robust and innovative pipeline and an experienced team. I look forward to working with Raj and the management team to sustainably grow the business and bring meaningful value to patients, clinicians and investors," Mr. Lang said.

Mr. Lang comes to Aerie with over 25 years of experience delivering financial, strategic and operational solutions, with deep expertise in health care and a particular focus on the biopharma sector. He has held leadership roles at well-recognized global and boutique investment banks. In addition, he has a long track record of working with management teams and boards to optimize companies’ growth plans, capital structures and return on capital. Over the course of his career, he helped raise ~$105 billion in financing and growth capital and advised on more than 40 M&A and business development transactions totaling more than $25 billion in deal value.